Trial Profile
A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Orlistat (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 11 Aug 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2008-006986-10).
- 20 Mar 2012 New trial record